Evidence map›Paper›PMID 32838191›Full record

ArticleSN comprehensive clinical medicine2020

COVID-19 Recommendations for Patients with Cancer: The post-COVID-19 Era.

Nabil Ismaili

Abstract read
In one paragraph

Article in SN comprehensive clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. COVID-19: The Impact in Oncology Care.SN comprehensive clinical medicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Nabil IsmailiDepartment of Medical Oncology, Cheick Khalifa International University Hospital, Casablanca, Morocco.ORCID 0000-0001-5786-5134

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the extent of the COVID-19 infection worldwide, the impact of the pandemic in our country remains low thanks to containment measures. On July 11, 2020, the spread of the virus in Morocco has caused more than 15,000 cases and 243 deaths. It is important to note that cancer patients are at high risk of developing COVID-19 disease. However, little changes have been made in our clinical practice in cancer management. Medical care aims are to ensure optimal treatment while minimizing the risk of COVID-19 transmission. Management should be discussed in a multidisciplinary team meeting, and any decision made, particularly influenced by the context of the COVID-19 pandemic, should be discussed and shared with the patient. In this article, we summarize our practical recommendations and how we prioritize cancer patient care during the post-COVID-19 phase.

Indexed as

CancerChemotherapyCOVID-19Follow-upRadiotherapySurgery

Identifiers

PMID32838191
PMCPMC7429086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.